Innoviva Total Liabilities 2010-2024 | INVA
Innoviva total liabilities from 2010 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
Innoviva Annual Total Liabilities
(Millions of US $) |
| 2023 |
$569 |
| 2022 |
$666 |
| 2021 |
$400 |
| 2020 |
$392 |
| 2019 |
$383 |
| 2018 |
$389 |
| 2017 |
$610 |
| 2016 |
$732 |
| 2015 |
$752 |
| 2014 |
$745 |
| 2013 |
$382 |
| 2012 |
$214 |
| 2011 |
$346 |
| 2010 |
$354 |
| 2009 |
$370 |
Innoviva Quarterly Total Liabilities
(Millions of US $) |
| 2024-06-30 |
$559 |
| 2024-03-31 |
$564 |
| 2023-12-31 |
$569 |
| 2023-09-30 |
$561 |
| 2023-06-30 |
$563 |
| 2023-03-31 |
$568 |
| 2022-12-31 |
$666 |
| 2022-09-30 |
$686 |
| 2022-06-30 |
$572 |
| 2022-03-31 |
$555 |
| 2021-12-31 |
$400 |
| 2021-09-30 |
$395 |
| 2021-06-30 |
$395 |
| 2021-03-31 |
$392 |
| 2020-12-31 |
$392 |
| 2020-09-30 |
$387 |
| 2020-06-30 |
$387 |
| 2020-03-31 |
$382 |
| 2019-12-31 |
$383 |
| 2019-09-30 |
$392 |
| 2019-06-30 |
$396 |
| 2019-03-31 |
$390 |
| 2018-12-31 |
$389 |
| 2018-09-30 |
$386 |
| 2018-06-30 |
$494 |
| 2018-03-31 |
$489 |
| 2017-12-31 |
$610 |
| 2017-09-30 |
$614 |
| 2017-06-30 |
$669 |
| 2017-03-31 |
$726 |
| 2016-12-31 |
$732 |
| 2016-09-30 |
$738 |
| 2016-06-30 |
$741 |
| 2016-03-31 |
$750 |
| 2015-12-31 |
$752 |
| 2015-09-30 |
$761 |
| 2015-06-30 |
$756 |
| 2015-03-31 |
$749 |
| 2014-12-31 |
$745 |
| 2014-09-30 |
$747 |
| 2014-06-30 |
$793 |
| 2014-03-31 |
$342 |
| 2013-12-31 |
$382 |
| 2013-09-30 |
$336 |
| 2013-06-30 |
$509 |
| 2013-03-31 |
$500 |
| 2012-12-31 |
$214 |
| 2012-09-30 |
$211 |
| 2012-06-30 |
$210 |
| 2012-03-31 |
$212 |
| 2011-12-31 |
$346 |
| 2011-09-30 |
$342 |
| 2011-06-30 |
$341 |
| 2011-03-31 |
$343 |
| 2010-12-31 |
$354 |
| 2010-09-30 |
$354 |
| 2010-06-30 |
$358 |
| 2010-03-31 |
$363 |
| 2009-12-31 |
$370 |
| 2009-09-30 |
$359 |
| 2009-06-30 |
$366 |
| 2009-03-31 |
$359 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$1.205B |
$0.310B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
